Secondary prophylaxis with factor IX concentrates: Continuous infusion

Blood Transfusion

Volumn 6, Issue SUPPL. 2, 2008, Pages

  Morfini, Massimo ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Continuous infusion; Factor IX; Pharmacokinetics

Indexed keywords

BETAFACT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; GASTROINTESTINAL HEMORRHAGE; HEMOPHILIA; HEMOPHILIA B; IMMUNOAFFINITY CHROMATOGRAPHY; INFECTION; ION EXCHANGE CHROMATOGRAPHY; SUBSTITUTION THERAPY;

BLOOD COAGULATION FACTORS; BLOOD LOSS, SURGICAL; CATHETERIZATION, CENTRAL VENOUS; CLINICAL TRIALS AS TOPIC; FACTOR IX; HALF-LIFE; HEMOPHILIA B; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; ISOANTIBODIES; METABOLIC CLEARANCE RATE; MULTICENTER STUDIES AS TOPIC; PLASMA; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; SECONDARY PREVENTION;

EID: 56649097252     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2008.0033-08     Document Type: Conference Paper

References (32)

1. Hermens WTH. Dose calculation of human factor VIII and factor IX concentrates for infusion therapy. In Brinkhous K M and Hemker H C, Handbook of hemophilia, pag.569-89, American Elsevier Riblishing Co., New York, 1975.
2. Miller GJ, Howarth DJ, Attfield JC, et al. Haemostatic factors in human peripheral afferent lymph. Thromb Haemost 2000;83:427-32.
3. Björkman S, Carlsson M, Berntorp E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur J Clin Pharmacol 1994;46:325-32.
4. Cheung WF, van den Born J, Kühn K, et al. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996;93:11068-73.
5. Mayhew M, Handford P, Brownlee GG. The binding of natural variants of human factor IX to endothelial cells. FEBS Lett 1994;341:74-8.
6. Longo G, Cinotti S, Filimberti E, et al. Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. Eur J Haematol 1987;39:426-33.
7. Morfini M, Longo G, Berntorp E, et al. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. Thromb Res 1993;71:175-84.
8. Poon MC, Aledort LM, Anderle K, et al. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995;35:319-23.
9. Thomas DP, Hampton KK, Dasani H, et al. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol 1994;87:782-8.
10. Goudemand J, Peynet J, Chambost H, et al. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Thromb Haemost 1998;80:919- 24.
11. Kim HC, McMillan CW, White GC, et al. Purified factor IX using monoclonal irnmunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates. Blood 1992;79:568-75.
12. Kim HC, McMillan CW, White GC, et al. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. Semin Hematol 1990;27(2 Suppl 2):30-5.
13. Köhler M, Seifried E, Hellstern P, et al. In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards. Blut 1988;57:341-5.
14. White GC 2nd, Shapiro AD, Kurczynski EM, et al. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor concentrates in patients with hemophilia B. The Mononine Study Group. Thromb Haemost 1995;73:779-84.
15. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophiha. 2007;13:2-8.
16. Longo G, Matucci M, Morfini M, et al. A calculator program for individualizing factor VIII dosage. Drug Intell Clin Pharm 1984;18:726- 30.
17. Messori A, Longo G, Morfini M, et al. Individualization of factor VIII dosage. J Clin Hosp Pharm 1984;9:95-103.
18. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia 2005;11:571-82.
19. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia 2003;9 (Suppl 1):101-8.
20. Batarova A, Martinowiz U. Continuous infusion of coagulation factors: current opinion A. Current Opinion in Hematology 2006;13:308-15.
21. White GC 2nd, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997;78:261-5.
22. Ewenstein BM, Joist JH, Shapiro AD, et al. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002;42:190-7.
23. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001;40:815-32.
24. Hoots WK, Leissenger C, Stabler S, et al. Continuous intravenous infusion of plasma-derived factor IX concentrate (Mononine) in haemophilia B. Haemophilia 2003;9:164-72.
25. Meunier S, Chamourad V, Lienhart A, et al. Continuous infusion of factor IX SD-15 (Betafact) during surgeries in patient with haemophilia B: efficacy and safety profile. Haemophilia 2002;8:571 (abstract).
26. Chowdary P, Dasani H, Jones JA, et al. Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. Haemophilia 2001;7:140-5.
27. Ragni MV, Pasi KJ, White GC, et al; Recombinant FIX Surgical Study Group. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 2002;8:91-7.
28. Martinowitz UP, Schulman S. Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B. Acta Haematol 1995;94 (Suppl 1):35-42.
29. White B, Cotter M, Byrne M, et al. High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice? Haemophiha 2000;6:113-5.
30. Sharathkumar A, Lillicrap D, Blanchette VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003;1:1228-36.
31. Koestenberger M, Leschnik B, Muntean W. More on: mild hemophilia A and inhibitor development. J Thromb Haemost 2004;2:676.
32. Mulcahy R, Walsh M, Scully MF. Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre. Haemophilia 2005;11:208-15.